

1 **Title:** Comparative Clinical Evaluation of the Alinity m STI Multiplex PCR Assay for
2 Diagnosis and Surveillance of *Chlamydia trachomatis*, *Neisseria gonorrhoea*,
3 *Trichomonas vaginalis*, and *Mycoplasma genitalium*

4
5 Amorce Lima, PhD^{1*}, Dominic Uy, MB¹, Joshua Kostera, PhD², Suzane Silbert, PhD¹

6
7 ¹ Tampa General Hospital, Tampa, FL, USA

8 ² Abbott Laboratories, Des Plaines, IL, USA

9
10 ***Corresponding author:** Amorce Lima, PhD

11 Tampa General Hospital

12 1 Tampa General Circle

13 Tampa, FL 33606 USA

14 Phone: 813-660-6357

15 Email: alima@tgh.org

16
17 **Word counts:** summary 26; abstract 269; main text 3111

18 **Number of references:** 30

19 **Number of figures:** 5

20 **Number of tables:** 2

21
22 **Conflicts of Interest and Source of Funding**

23 Joshua Kostera is an employee of Abbott Laboratories. This study was funded by a
24 grant from Abbott Laboratories.

25 **Summary**

26 Evaluation of Alinity m STI clinical performance for diagnosis and surveillance of CT,

27 NG, TV, and MG in a large academic medical center in the US.

28 **Abstract**

29 **Background:** *Chlamydia trachomatis* (CT) and *Neisseria gonorrhoeae* (NG) are
30 routinely tested and reported; however, *Trichomonas vaginalis* (TV) is the most
31 common STI in the US and the prevalence of *Mycoplasma genitalium* (MG)
32 infections is likely higher than estimated. We examined the clinical performance of
33 the Alinity m STI assay for detection and surveillance of CT/NG/TV/MG in urine
34 specimens from patients at a large academic medical center.

35 **Methods:** Prevalence of mono- and co-infections on Alinity m STI pathogens and
36 predictors of a positive result were identified. Alinity m STI and Aptima Combo 2
37 CT/NG and TV assay (Panther System) results were compared, with discrepant
38 results run on the cobas 6800 CT/NG, TV and MG assays. Analyzer turnaround
39 times (TAT) were determined for Alinity m and Panther systems.

40 **Results:** 199 urine specimens were included. Age ≥ 25 years, collection outside the
41 emergency department (ED), and asymptomatic status were predictive of TV or MG
42 infection; symptomatic status was the only predictor of CT or NG infection. Overall
43 agreement rates for the Alinity m, Aptima, and cobas assays ranged from 86.4% to
44 99.5% for the four pathogens. TV and MG infections comprised 54% of the positive
45 samples and were more often asymptomatic than CT and NG infections. Analyzer
46 TAT (onboard to result reporting) was 4 hours 45 minutes for the Aptima CT/NG, 3
47 hours 25 minutes for Aptima TV, and 1 hour 55 minutes for Alinity m STI assay.

48 **Conclusions:** The Alinity m STI assay allows for fast and simultaneous detection of
49 the four major STI pathogens, which can facilitate surveillance and provide accurate
50 results to help clinicians diagnose for initiation of appropriate treatment.

51

52 **Key words:** surveillance, nucleic acid amplification test, screening, DNA

54 **Introduction**

55 The most recent CDC surveillance data indicates that 2.5 million STIs were reported
56 in 2021, an increase of almost 3% from 2020 (1). The four most common STI
57 pathogens are *Chlamydia trachomatis* (CT), *Neisseria gonorrhoeae* (NG),
58 *Trichomonas vaginalis* (TV), and *Mycoplasma genitalium* (MG). Of these, TV is the
59 most common, with 1.2% prevalence among 2013-2014 NHANES participants (2);
60 however, TV is not considered reportable by CDC (3, 4). Current guidelines
61 recommend TV screening only in high-risk populations (3). As the majority of
62 individuals with TV infection are asymptomatic, it can remain undiagnosed and
63 untreated for years, leading to severe consequential health outcomes such as pelvic
64 inflammatory disease, urethritis, and infertility. MG has emerged as an STI pathogen
65 of concern with drug resistant MG placed on CDC's Watch List in 2019 (5). Yet MG
66 is not classified as reportable by CDC; current guidelines recommended MG testing
67 in only a small subset of patients with recurrent urethritis or cervicitis (3). Thus, the
68 true prevalence of MG infection is not clear and is likely higher than expected (6).

69

70 Untreated STIs have significant long-term health consequences and inflict a
71 substantial economic medical burden (7). Additionally, NG, TV, and MG infections
72 are associated with increased risk for acquiring or transmitting HIV (3, 4, 8). Timely
73 diagnosis of STIs is essential to reduce transmission and initiate treatment (3), but
74 diagnosis based on patient symptoms alone can be challenging. Co-infections by
75 more than one pathogen can cause overlapping symptoms that confound both
76 diagnosis and initiation of appropriate therapy. Inaccurate diagnosis leading to
77 inappropriate or inconsistent treatment can lead to the emergence of multidrug
78 resistant strains (9-11).

79

80 Guidelines recommend screening for the reportable pathogens, CT and NG, with
81 nucleic acid amplification tests (NAATs) to help reduce transmission and guide
82 treatment (12, 13). Similar NAAT-based surveillance programs for TV and MG would
83 be expected to identify subclinical or asymptomatic infections, refine treatment
84 algorithms, and reduce transmission rates (3, 14, 15). Because sequential testing for
85 each pathogen can prolong the time to diagnosis and delay initiation of appropriate
86 treatment, NAATs have been developed for simultaneous detection of multiple
87 pathogens from a single specimen.

88

89 The Alinity m STI assay (Abbott Laboratories, Des Plaines, IL, USA) is an in vitro
90 multiplex RT-PCR assay that is designed for qualitative and simultaneous detection
91 of CT, NG, MG, and TV in various urogenital and extragenital specimens. The
92 objective of this study was to evaluate the Alinity m STI assay and compare the
93 results with our standard of care (SOC) STI tests, the Aptima Combo 2 CT/NG and
94 the Aptima TV assays, run on the Panther system (Hologic, Marlborough, MA) for
95 urine specimens collected from patients at a large academic medical center in the
96 United States. We also examined the utility of the Alinity m STI assay for surveillance
97 of TV and MG infection.

98

99 **Materials and Methods**

100 ***Specimens and setting***

101 199 residual de-identified urine specimens from consecutive inpatients, outpatients,
102 and patients in the emergency department (ED) at Tampa General Hospital (TGH;
103 Tampa, Florida, USA) were included in the study after SOC testing. No inclusion or

104 exclusion criteria were applied. The study was conducted following GCLP and in
105 accordance with the Declaration of Helsinki, under IRB# 1301043.

106

107 ***Specimen collection and disposition***

108 Approximately 2 mL of first catch urine specimen was transferred from the primary
109 urine collection container to an Aptima Urine Specimen Transport Tube for SOC
110 testing on the Panther system (Figure 1). Two additional 5-mL aliquots from the
111 primary urine collection container were pipetted into cryogenic vials: Aliquot #1 was
112 transferred to the Alinity m multi-collect tube which was used for testing on the Alinity
113 m STI assay and Aliquot #2 was used for referral testing to confirm MG positives on
114 Alinity m and resolve any discrepant results.

115

116 All MG-positive specimens and at least 5 MG-negative specimens on Alinity m STI
117 with sufficient remaining volume were sent to the University of Alabama STD
118 Diagnostics Lab (UAB; Birmingham, AL, USA), to be tested for CT, NG, TV, and MG
119 on the cobas 6800 system (Roche, Branchburg, NH, USA). All specimens with
120 discrepant results on the Aptima and Alinity m assays with sufficient volume for
121 Aliquot #2 were also sent to UAB for testing with the cobas 6800 CT/NG, TV and MG
122 assays.

123

124 ***Assay platforms***

125 The Alinity m STI assay (Abbott Laboratories) was run on a single Alinity m analyzer
126 at TGH according to the manufacturer's instructions using reagents that was not yet
127 approved by the FDA for that purpose. The Alinity m STI assay primers and probes
128 amplify and detect an endogenous human DNA sequence as validity control (cellular

129 control, CC) and an exogenous internal control (IC) is used to confirm the absence of
130 PCR inhibitors in the test specimen. For this study, 2.1 mL of each collected urine
131 specimen was transferred from Aliquot #1 to an Alinity m multi-Collect tube for
132 testing and the analyzer was programmed to test all four STI pathogens (CT, NG,
133 MG, and TV). Alinity m reagents were left onboard the analyzer for 10-30 days.

134

135 The Aptima Combo 2 for CT/NG and Aptima TV assays were run on the Panther
136 system (Hologic, Inc.) at TGH. If clinical orders were for CT/NG testing only, then TV
137 testing was performed using the same specimen. Because onboard stability of the
138 Aptima reagents is 72 hours, TV testing was performed in batches. Upon completion
139 of testing, the reagents were removed from the Panther instrument and refrigerated.
140 If TV testing was not done on the same day as CT/NG testing, specimens were
141 stored at 2-8°C until the next batch run.

142

143 The cobas 6800 CT/NG assay and cobas 6800 TV/MG assays were run at UAB. All
144 assays were run following the manufacturers' instructions.

145

146 ***Workflow study***

147 Total TAT for the Alinity m STI assay were calculated based on timepoints entered
148 into the laboratory information system and electronic medical record. The average
149 time from specimen receipt to results reporting and from specimen loading onto the
150 analyzer to results reporting were tracked.

151

152 ***Data analysis***

153 The prevalence of each analyte and co-infections in the study population were

154 determined based on the Alinity m STI assay results. Positive, negative, and overall
155 percent agreement (PPA, NPA, OPA) and 95% confidence intervals (CIs) and kappa
156 values were determined for results from the Alinity m STI assay and the comparator
157 assays. Odds ratios and 95% CIs were calculated to identify variables predictive of
158 positive Alinity m STI assay results.

159

160 **Results**

161 **Study cohort characteristics and test results**

162 Urine specimens from 199 patients were included in the study; demographic
163 characteristics are shown in Table 1. The majority of specimens were collected from
164 females and in the inpatient setting. Median patient age was 29 years; of note, a
165 patient between the age of 6-10 was included, but was the only patient under 16
166 years of age and was negative for all pathogens tested on the Aptima CT/NG and TV
167 assays and Alinity m STI assay (CT/NG/TV/MG). The cohort was diverse, with
168 slightly more Black patients than White or Hispanic patients. Eighteen patients in the
169 “Other” category were Asian, mixed-race, Middle Eastern, or chose not to identify
170 their racial/ethnic background.

171

172 Forty-three patients had positive Alinity m assay results (Table 1). There were 7 CT,
173 4 NG, 12 TV, and 11 MG mono-infections; 3 CT/NG co-infections; 3 CT/MG co-
174 infections; 2 NG/TV co-infections; and 1 TV/MG co-infection. No triple or quadruple
175 co-infections were detected. TV and MG infections comprised more than half (54%)
176 of the positive samples and 14% were co-infections with CT or NG (Figure 2A). Only
177 25% of positive results were CT or NG mono-infections and 7% were CT/NG co-
178 infections. The mean age of patients with TV or MG mono-infections or TV/MG co-

179 infection was 32 years, 5 years older than the mean age of patients with CT or NG
180 mono-infection or CT/NG co-infection. In this cohort, TV, MG, TV/MG, and
181 associated co-infections were mostly asymptomatic (20 asymptomatic and 9
182 symptomatic), whereas CT, NG, CT/NG infections were more often symptomatic (10
183 symptomatic and 4 asymptomatic). The distribution of Alinity m STI positive results
184 varied based on site of specimen collection (Figure 2B). The vast majority of positive
185 specimens collected in the inpatient setting were from asymptomatic patients,
186 whereas the majority of positive specimens collected in the ED and all positive
187 specimens collected in the outpatient setting were from symptomatic patients.
188 Specimens were tested on 82 unique testing days over the course of 10 months.

189

190 ***Predictors of positive Alinity m STI assay results***

191 Factors that were most predictive of an assay result positive for TV or MG mono- or
192 co-infection were age ≥ 25 years, specimen collected at a site outside the ED, and
193 asymptomatic status (Figure 3A). The only factor predictive of CT, NG, or CT/NG
194 positive results was symptomatic status (Figure 3B). Specimen collection outside the
195 ED was somewhat predictive of a positive CT, NG, or CT/NG result.

196

197 ***Comparative performance of STI NAATs***

198 Agreement between Alinity m STI, Aptima CT/NG, Aptima TV, and cobas MG assay
199 results is summarized in Table 2. Overall percent agreement (OPA) between Alinity
200 m STI and comparator assay results was 99.5% (95%CI: 97.2%, 99.9%) for CT,
201 99.5% (95%CI: 97.2%, 99.9%) for NG, 98.4% (95%CI: 95.5%, 99.5%) for TV, and
202 86.4% (95%CI: 66.7%, 95.3%) for MG.

203

204 For CT, 1 specimen collected from an asymptomatic female patient in her 20s was
205 CT-positive on Aptima, CT-negative on Alinity m, and CT-positive on cobas. The
206 review of the Aptima CT/NG relative light units (RLU) for this specimen was 829 vs
207 mean RLU for all CT-positive specimens was 1125 (SD 227), indicating a low CT
208 concentration in the specimen that was not detected by Alinity m STI.

209

210 One specimen collected from an asymptomatic female patient under 20 years old
211 was NG-positive on Aptima and NG-negative on Alinity m. The RLU on Aptima
212 CT/NG for this specimen was 563, more than 3 SD from the mean RLU for all NG-
213 positive specimens of 1299 (SD 154). The specimen was also found to be NG-
214 negative on cobas, in agreement with the Alinity m STI result.

215

216 Two specimens were found to be TV-positive on Aptima and TV-negative on Alinity
217 m STI assay. The first was from an asymptomatic male patient in his 50s that was
218 TV-negative on cobas. The specimen was not positive for any other pathogen. The
219 specimen RLU on Aptima TV was 133, more than 2 SD from the mean RLU of 1324
220 (SD 369) for all TV-positive specimens from asymptomatic patients. The second
221 specimen, from an asymptomatic female patient in her early 40s, was TV-positive on
222 cobas. The TV RLU was 1528, within 1 SD of the mean RLU of 1324. One specimen
223 from an asymptomatic female in her 30s was TV-negative on Aptima, TV-positive on
224 Alinity m, and TV-negative on cobas.

225

226 Three specimens were MG-negative on cobas but MG-positive on Alinity m. One
227 specimen from a symptomatic female patient and another from an asymptomatic
228 female patient in their 20s were negative for CT/NG/TV on Alinity m, negative for

229 CT/NG and TV on Aptima, and negative for CT/NG and TV/MG on cobas. The third
230 specimen, from an asymptomatic female patient in her 30s, was also TV-positive on
231 the Alinity m, Aptima, and cobas assays. The cause for the discrepancy between
232 Alinity m and cobas MG results could potentially be attributable to neat sample
233 degradation between collection and testing with cobas or assay sample type
234 sensitivities.

235

236 For the 8 specimens with discrepant results on the Aptima, Alinity m, and cobas
237 assays, there was no significant difference in the Alinity m IC and CC cycle number
238 (CN) values compared to the average IC and CC CN values of all specimens in
239 cohort (see Table, Supplemental Digital Content 1).

240

241

242 ***Aptima and Alinity m STI assay performance by symptom status***

243 Although the assays are qualitative, we compared assay readouts (RLU for Aptima
244 and CN for Alinity m) across target pathogens and in specimens from symptomatic
245 and asymptomatic patients. Aptima RLUs were significantly higher for specimens
246 from symptomatic patients with CT/NG co-infection compared to those with CT, NG,
247 or TV mono-infection or in asymptomatic patients (Figure 4A). It is not surprising that
248 higher RLUs were seen with co-infections, as they would elicit a double probe
249 response. CN values for specimens run on the Alinity m STI assay were consistently
250 between 10 and 40 and did not differ by symptom status (Figure 4B).

251

252 ***Aptima and Alinity m STI workflow analysis***

253 We compared the workflows for each assay for 199 specimens. The average overall
254 turnaround time, from receipt of the specimen in the lab to results reporting, for the
255 Alinity m STI assay for all four analytes was 6 hours 59 minutes (n=199; Figure 5A).
256 The overall turnaround time was 8 hours 28 minutes (n=199) for the Aptima CT/NG
257 assay and 80 hours 56 minutes (n=128) for the Aptima TV assay, reflecting the
258 batching of specimens. To assess workflow independent of batching, we examined
259 the turnaround time from loading the specimen on the analyzer to results reporting
260 for the three assays (Figure 5B). The average time from onboarding to result was 3
261 hours 25 minutes for the Aptima CT/NG assay, 3 hours 25 minutes for the Aptima TV
262 assay, and 1 hour 55 minutes for the Alinity m STI assay for CT/NG/TV/MG.

263

264 **Discussion**

265 In this study, we found high agreement rates between the Alinity m STI assay and
266 the Aptima Combo 2 and TV assays for CT/NG and TV (OPA \geq 98.4%) or cobas
267 TV/MG assay for MG (OPA=86.4%). Discrepant specimens that were negative on
268 Alinity m were primarily seen in asymptomatic patients where a CN value was not
269 generated or had high CN values greater than the assay cutoff cycle, indicating low
270 levels of the pathogen target. These findings are consistent with a previous study
271 demonstrating concordance of results from the Alinity m STI assay and RealTime
272 CT/NG/TV assay run on the m2000 system (16).

273

274 The prevalences of infection and co-infection in our study indicate that TV and MG
275 infections are likely being missed. Only 2 out of the 14 positive TV samples had a
276 microscopy test performed and both were negative. Current practice at our institution
277 is consistent with CDC guidance for CT and NG screening (3), with specimens run

278 on the Aptima CT/NG assay as the SOC test. We do not routinely test for TV, unless
279 ordered by the provider and do not test for MG. In our cohort, 68% of positive
280 samples on Alinity m were TV or MG positive (53% mono-infection) and were more
281 likely to be from asymptomatic patients.

282

283 Our findings are consistent with the literature that most TV/MG infections are
284 asymptomatic. The Swiss STAR trial screened high-risk women and found a
285 prevalence of undiagnosed TV up to 10.4% and MG up to 6.7% (17). A US study of
286 374 female adolescents in juvenile detention found that 8% tested positive for TV
287 and half of these were asymptomatic (18). Another study of men who have sex with
288 men (MSM) with HIV who were screened for MG found a 20% prevalence, 93% of
289 which were asymptomatic (19). Addition of TV and MG testing would reduce the
290 likelihood of missed infections, decrease the risk of transmission, and improve
291 appropriate antimicrobial use.

292

293 Identification of factors predictive of positive TV and MG results on Alinity m STI or
294 other NAATs could help inform adjustments to STI screening algorithms (1, 3) to
295 ensure that asymptomatic infections are detected and treated. In our study, the
296 mean age of patients with TV/MG-positive results was 5 years older than those with
297 CT/NG-positive results. This is consistent with several surveillance studies showing
298 that TV/MG infections are more likely to be diagnosed at a later age than CT/NG
299 infections (3, 20-22). A recent US study of NHANES data found that women,
300 smokers, non-Hispanic Black patients, and patients of lower socioeconomic status
301 are more likely to have a TV infection (23). In contrast to our findings, a study of a
302 high-risk population of women in New Mexico found that MG infection was more

303 prevalent in younger than older women (24). Rigorous, nationwide studies of
304 predictors of MG infection are needed to develop evidence-based recommendations
305 for MG testing.

306

307 The distribution of positive Alinity m results by collection site illustrated that the ED is
308 utilized to confirm infection in symptomatic patients. Studies suggest that a growing
309 number of STIs are being diagnosed in the ED setting, possibly related to closure of
310 STI clinics and increased utilization of the ED for primary care (25, 26). STI testing in
311 the ED may help identify individuals with asymptomatic infection, allowing earlier
312 initiation of treatment to stop transmission chains. A recent study developed a
313 prediction model for identifying patients as candidates for CT/NG/TV testing in the
314 ED, based on age, marital status, race, findings from vaginal wet prep, and urinalysis
315 (27).

316

317 In the workflow analysis, Alinity m STI reduced turnaround times compared to
318 Aptima by removing the need for batching of TV assays. Simultaneous testing of all
319 four pathogens also decreased the onboard to result turnaround times. Our findings
320 are consistent with a previous report of faster turnaround times with the Alinity m STI
321 assay compared to the Abbott RealTime assay run on the m2000 instrument (28). A
322 workflow study of the Alinity m platform also demonstrated reduced the time to
323 diagnosis and treatment initiation (29). More rapid results reporting has implications
324 for management of STIs in the ED setting. A recent study suggested that rapid NAAT
325 for STIs may help direct appropriate utilization of antimicrobials in the ED and reduce
326 the risk of treatment resistance (30).

327

328

329 This was a single-center study, which may limit the generalizability of our findings;
330 however, we utilized a third assay system run at a separate facility to resolve
331 discrepancies in assay results. The Aptima system was not used to test for MG,
332 which prevented a direct comparison to the Alinity m STI assay. This study also only
333 utilized urine specimens; additional studies are needed to evaluate the performance
334 of the Alinity m STI assay with other genital and extragenital specimen types and
335 collection methods. Despite these limitations, this study utilized a convenience
336 sample with no inclusion or exclusion criteria, which led to a diverse study cohort.
337 We collected specimens from multiple sites in the medical center, and tested
338 throughout the year to ensure that the sample was not enriched for certain peak
339 periods.

340

341 Our findings support the surveillance of MG and TV, which often remain as
342 asymptomatic infections that serve as ongoing transmission reservoirs. Symptoms
343 alone are non-diagnostic and can overlap significantly between CT, NG, TV, and
344 MG. The Alinity m STI assay allows for simultaneous detection of the four major STI
345 pathogens in a single assay, which can simplify the implementation of MG/TV
346 surveillance programs in health systems that already report NG and CT infections.
347 TV and MG surveillance programs can inform evidence-driven changes in the STI
348 diagnostic algorithm, with multiplex assays moving patients more quickly to
349 diagnosis and initiation of the most appropriate treatment.

350

351 **Acknowledgements**

352 The authors would like to thank Yan Zhang, PhD, for assistance with the statistical

353 analysis. Stacey Tobin, PhD, provided editorial support for manuscript preparation,
354 with compensation from Abbott Laboratories.

355

356 **References**

- 357 1. Centers for Disease Control and Prevention. Sexually Transmitted Disease
358 Surveillance 2021. 2023; Accessed at
359 <https://www.cdc.gov/std/statistics/2021/default.htm>. Accessed May 23 2023.
- 360 2. Patel EU, Gaydos CA, Packman ZR, Quinn TC, Tobian AAR. Prevalence and
361 Correlates of Trichomonas vaginalis Infection Among Men and Women in the United
362 States. Clin Infect Dis. 2018;67(2):211-7.
- 363 3. Workowski KA, Bachmann LH, Chan PA, et al. Sexually Transmitted Infections
364 Treatment Guidelines, 2021. MMWR Recomm Rep. 2021;70(4):1-187.
- 365 4. Muzny CA. Why Does Trichomonas vaginalis Continue to be a "Neglected" Sexually
366 Transmitted Infection? Clin Infect Dis. 2018;67(2):218-20.
- 367 5. Centers for Disease Control and Prevention. Antibiotic Resistance Threats in the
368 United States 2019. Atlanta, GA: US Department of Health and Human Services;
369 2019; Accessed at [https://www.cdc.gov/drugresistance/pdf/threats-report/2019-ar-](https://www.cdc.gov/drugresistance/pdf/threats-report/2019-ar-threats-report-508.pdf)
370 [threats-report-508.pdf](https://www.cdc.gov/drugresistance/pdf/threats-report/2019-ar-threats-report-508.pdf). Accessed August 28 2023.
- 371 6. Manhart LE, Holmes KK, Hughes JP, Houston LS, Totten PA. Mycoplasma
372 genitalium among young adults in the United States: an emerging sexually
373 transmitted infection. Am J Public Health. 2007;97(6):1118-25.
- 374 7. Chesson HW, Spicknall IH, Bingham A, et al. The estimated direct lifetime medical
375 costs of sexually transmitted infections acquired in the United States in 2018. Sex
376 Transm Dis. 2021;48(4):215-21.
- 377 8. Kissinger P, Adamski A. Trichomoniasis and HIV interactions: a review. Sex Transm
378 Infect. 2013;89(6):426-33.

- 379 9. Sethi S, Zaman K, Jain N. Mycoplasma genitalium infections: current treatment
380 options and resistance issues. *Infect Drug Resist.* 2017;10:283-92.
- 381 10. Getman D, Jiang A, O'Donnell M, Cohen S. Mycoplasma genitalium Prevalence,
382 Coinfection, and Macrolide Antibiotic Resistance Frequency in a Multicenter Clinical
383 Study Cohort in the United States. *J Clin Microbiol.* 2016;54(9):2278-83.
- 384 11. Unemo M, Jensen JS. Antimicrobial-resistant sexually transmitted infections:
385 gonorrhoea and Mycoplasma genitalium. *Nat Rev Urol.* 2017;14(3):139-52.
- 386 12. Recommendations for the laboratory-based detection of Chlamydia trachomatis and
387 Neisseria gonorrhoeae--2014. *MMWR Recomm Rep.* 2014;63(Rr-02):1-19.
- 388 13. Nelson HD, Zakher B, Cantor A, Deagas M, Pappas M. Screening for Gonorrhea and
389 Chlamydia: Systematic Review to Update the U.S. Preventive Services Task Force
390 Recommendations. Rockville (MD); 2014.
- 391 14. Muzny CA, Burkholder GA, Fry KR, Austin EL, Schwebke JR. Trichomonas vaginalis
392 Nucleic Acid Amplification Testing at an Urban HIV Clinic. *Sex Transm Dis.*
393 2016;43(8):483-8.
- 394 15. Muzny CA, Blackburn RJ, Sinsky RJ, Austin EL, Schwebke JR. Added benefit of
395 nucleic acid amplification testing for the diagnosis of Trichomonas vaginalis among
396 men and women attending a sexually transmitted diseases clinic. *Clin Infect Dis.*
397 2014;59(6):834-41.
- 398 16. Herrmann B, Malm K. Comparison between Abbott m2000 RealTime and Alinity m
399 STI systems for detection of Chlamydia trachomatis, Neisseria gonorrhoeae, and
400 Mycoplasma genitalium. *Eur J Clin Microbiol Infect Dis.* 2021.
- 401 17. Vernazza PL, Rasi M, Ritzler M, et al. The Swiss STAR trial - an evaluation of target
402 groups for sexually transmitted infection screening in the sub-sample of women.
403 *Swiss Med Wkly.* 2020;150:w20393.
- 404 18. Oshin E, Eissa MA, Benjamins LJ, Barratt MS, Beyda RM. Trichomonas Vaginalis
405 Infections Among Youth in Detention in the Southeastern United States. *J Pediatr*
406 *Adolesc Gynecol.* 2022;35(3):368-70.

- 407 19. Ring A, Balakrishna S, Imkamp F, et al. High Rates of Asymptomatic *Mycoplasma*
408 *genitalium* Infections With High Proportion of Genotypic Resistance to First-Line
409 Macrolide Treatment Among Men Who Have Sex With Men Enrolled in the Zurich
410 Primary HIV Infection Study. *Open Forum Infect Dis*. 2022;9(6):ofac217.
- 411 20. Flagg EW, Meites E, Phillips C, Papp J, Torrone EA. Prevalence of *Trichomonas*
412 *vaginalis* Among Civilian, Noninstitutionalized Male and Female Population Aged 14
413 to 59 Years: United States, 2013 to 2016. *Sexually Transmitted Diseases*.
414 2019;46(10).
- 415 21. Peterman TA, Tian LH, Metcalf CA, Malotte CK, Paul SM, Douglas JM, Jr. Persistent,
416 undetected *Trichomonas vaginalis* infections? *Clin Infect Dis*. 2009;48(2):259-60.
- 417 22. Sutton M, Sternberg M, Koumans EH, McQuillan G, Berman S, Markowitz L. The
418 prevalence of *Trichomonas vaginalis* infection among reproductive-age women in the
419 United States, 2001-2004. *Clin Infect Dis*. 2007;45(10):1319-26.
- 420 23. Tompkins EL, Beltran TA, Gelner EJ, Farmer AR. Prevalence and risk factors for
421 *Trichomonas vaginalis* infection among adults in the U.S., 2013-2014. *PLoS One*.
422 2020;15(6):e0234704.
- 423 24. Hammer A, Gravitt PE, Adcock R, Patterson N, Cuzick J, Wheeler CM. Burden of
424 *Mycoplasma genitalium* and Bacterial Coinfections in a Population-Based Sample in
425 New Mexico. *Sex Transm Dis*. 2021;48(12):e186-e9.
- 426 25. Hilbert SM, Reno HEL. Management of Patients with Sexually Transmitted Infections
427 in the Emergency Department. *Emergency Medicine Clinics of North America*.
428 2018;36(4):767-76.
- 429 26. Pearson WS, Peterman TA, Gift TL. An increase in sexually transmitted infections
430 seen in US emergency departments. *Preventive Medicine*. 2017;100:143-4.
- 431 27. Sheele JM, Niforatos JD, Elkins JM, Campos SC, Thompson CL. Prediction model
432 for gonorrhea, chlamydia, and trichomoniasis in the emergency department. *Am J*
433 *Emerg Med*. 2022;51:313-9.

- 434 28. Galindo LT, Hristov AD, Gentil LG, Scarpelli L, Santiago J, Levi JE. Performance
435 evaluation of the fully automated molecular system Alinity m in a high-throughput
436 central laboratory. *J Clin Virol.* 2021;137:104786.
- 437 29. Obermeier M, Pacenti M, Ehret R, et al. Improved molecular laboratory productivity
438 by consolidation of testing on the new random-access analyzer Alinity m. *Journal of*
439 *Laboratory Medicine.* 2020;44(6):319-28.
- 440 30. Rivard KR, Dumkow LE, Draper HM, Brandt KL, Whalen DW, Egwuatu NE. Impact of
441 rapid diagnostic testing for chlamydia and gonorrhea on appropriate antimicrobial
442 utilization in the emergency department. *Diagnostic Microbiology and Infectious*
443 *Disease.* 2017;87(2):175-9.
- 444
- 445
- 446

447 **Figure Legends**

448

449 **Figure 1.** Study design.

450

451 **Figure 2.** Alinity m STI assay positive specimens in the study cohort. (A) Distribution
452 by mono-infection or co-infection. (B) Number of positive specimens collected in
453 each setting from asymptomatic or symptomatic patients.

454

455 **Figure 3.** Factors predictive of an Alinity m STI assay positive result. Odds ratios
456 and 95% confidence intervals for factors predicting (A) a positive TV, MG, TV/MG,
457 TV/NG, or MG/CT result or (B) a positive CT, NG, or CT/NG result on the Alintiy m
458 STI assay.

459

460 **Figure 4.** (A) Aptima Combo 2 RLU values and (B) Alinity m STI assay CN values
461 for positive specimens from symptomatic and asymptomatic patients.

462

463 **Figure 5.** Turnaround times for Alinity m STI assay on the Alinity m platform
464 compared to Aptima CT/NG and TV assays run on the Panther platform. (A) Overall
465 turnaround from specimen arrival in the lab to results reporting. (B) Onboard
466 turnaround from specimen loading on the analyzer to results reporting.

467

468

469

470 **Tables**

471

472 **Table 1. Study Cohort Demographics**

	Full Cohort (N=199) n (%)	Cohort with Positive Alinity m STI Assay Results (N=43) n (%)
Collection site		
Inpatient	112 (56.3)	21 (48.8)
Emergency department	35 (17.6)	14 (32.6)
Outpatient	31 (15.6)	3 (7.0)
Labor & Delivery	16 (8.0)	4 (9.3)
Other	5 (2.5)	1 (2.3)
Sex		
Female	145 (72.9)	28 (65.1)
Male	54 (27.1)	15 (34.9)
Age (y), median (range)	29 (9-74)	27 (16-63)
Race/ethnicity		
Black	73 (36.7)	22 (51.2)
Hispanic	58 (29.1)	10 (23.3)
White	50 (25.1)	9 (20.9)
Other	18 (9.1)	2 (4.6)
Symptom status^a		
Asymptomatic	151 (76.0)	24 (55.8)
Symptomatic	45 (22.5)	19 (44.2)
Unknown	3 (1.5)	0 (0.0)

^a Symptom status data was available for n=199 of the full cohort and for all patients with positive Alinity m STI assay results.

473 **Table 2.** Agreement Between Alinity m STI Assay (CT/NG/TV/MG) and Aptima Combo 2 & Trichomonas vaginalis Assays (CT/NG
 474 and TV) or Cobas TV/MG Assay (MG) Results
 475

		Panther				Cobas			
		CT		NG		TV		MG	
		POS	NEG	POS	NEG	POS	NEG	POS	NEG
Alinity m	POS	13	0	9	0	14	1	10	3
	NEG	1	185	1	190	2	176	0	9
Agreement (95% CI)		OPA: 99.5% (97.2, 99.9%) PPA: 92.9% (68.5, 98.7%) NPA: 100.0% (98.0, 100.0%)		OPA: 99.5% (97.2, 99.9%) PPA: 94.4% (59.6, 98.2%) NPA: 100.0% (98.0, 100.0%)		OPA: 98.4% (95.5, 99.5%) PPA: 87.5% (64.0, 96.5%) NPA: 99.4% (96.9, 99.9%)		OPA: 86.4% (66.7, 95.3) PPA: 100.0% (72.2, 100.0) NPA: 75.0% (46.8, 91.1)	

476

477 **List of Supplemental Digital Content**


478

479 **Supplemental Digital Content 1.pdf**

480

481 **Figures**


482 **Figure 1**




483

484 **Figure 2**
485

A



B




486
487


488 **Figure 3**
489

A

490
491



B



492 **Figure 4**

493

4 **A**

496


497

498


499

500

501




B



502 **Figure 5**
503

A

504
505



B

